Publications
154
Citations
5,757
Est. group size
~2
Recurring co-author estimate
Active years
20
Publishing since 2007
Samir V. Parikh's research focuses on kidney diseases, particularly lupus nephritis, glomerulonephritis, and complement-mediated kidney disorders. Much of the work involves clinical trials testing new drugs (such as voclosporin and zetomipzomib) for lupus nephritis and other immune-related kidney conditions, alongside studies on disease mechanisms like complement activation and thrombotic microangiopathy. This research is relevant to students interested in kidney disease treatment, clinical trial design, and the biology of immune-mediated kidney damage.
Publication output rose sharply from 2019-2022, peaking around 2020, but has declined in the most recent years (2023-2025).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Spatial transcriptomic analysis of kidney biopsies identifies activation of complement and SPP1 networks in Staphylococcus infection-associated glomerulonephritis
Frontiers in Nephrology · 2026
- Safety and Preliminary Efficacy of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Journal of the American Society of Nephrology · 2025
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
Kidney International · 2024
- Clinicopathological differences between Bartonella and other bacterial endocarditis-related glomerulonephritis – our experience and a pooled analysis
Frontiers in Nephrology · 2024
- Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism–related vascular thrombosis with microvascular injury and its consequences
Kidney International · 2024
- 1007 Voclosporin for lupus nephritis: assessment of long-term safety and efficacy including renal outcome over three years of treatment in the phase 3 AURORA 1 and AURORA 2 studies
2024
- Role of plasminogen activated inhibitor-1 in the pathogenesis of anticoagulant related nephropathy
Frontiers in Nephrology · 2024
- Role of Versican in Cisplatin-Induced AKI to CKD Transition
Journal of the American Society of Nephrology · 2024
- Safety and Efficacy of <scp>Long‐Term</scp> Voclosporin Treatment for Lupus Nephritis in the Phase 3 <scp>AURORA</scp> 2 Clinical Trial
Arthritis & Rheumatology · 2023
- Clinical Evaluation and Management of Thrombotic Microangiopathy
Arthritis & Rheumatology · 2023
- POS1128 ZETOMIPZOMIB (KZR-616) TREATMENT RESULTS IN CLINICALLY MEANINGFUL RENAL RESPONSES IN PATIENTS WITH LUPUS NEPHRITIS
Annals of the Rheumatic Diseases · 2023
- Deletion of NuRD component <i>Mta2</i> in nephron progenitor cells causes developmentally programmed FSGS
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Repeat Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis
Journal of the American Society of Nephrology · 2023
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
American Journal of Nephrology · 2022
- Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Arthritis Care & Research · 2022
- Journal of the American Society of Nephrology×33
- Kidney International Reports×6
- Kidney International×5
- Arthritis & Rheumatology×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Brad H. Rovin
Medicine · The Ohio State University
- Isabelle Ayoub
Medicine · The Ohio State University
- Mahmoud Kallash
Medicine · The Ohio State University
- Salem Almaani
Medicine · The Ohio State University
- William E. Smoyer
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile